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OBJECTIVES Our study attempted to gain further understanding of the allosteric effects of human
autoantibodies on beta1-adrenergic receptor (beta1-AR) function.
BACKGROUND Recently, we reported on the existence of activating anti-beta1-AR antibodies in patients with
dilated cardiomyopathy (DCM 26% prevalence) or ischemic cardiomyopathy (ICM, 10%
prevalence); however, their functional effects have not yet been thoroughly characterized.
METHODS In this study we detected functionally active receptor-antibodies in 8 out of 30 DCM patients.
Their immunological and functional properties were analyzed using both synthetic receptor-
peptides and intact recombinant human beta1-AR, and were compared with those of
heterologous antibodies to selected beta1-AR domains generated in rabbits and mice.
RESULTS Rabbit, mouse, and human anti-beta1-AR against the second extracellular domain preferen-
tially bound to a native receptor conformation and impaired radioligand binding to the
receptor. However, their functional effects differed considerably: Rabbit and mouse antibodies
decreased both basal and agonist-stimulated cAMP production, whereas the patient anti-
bodies (n 5 8) increased basal, and six of them also increased agonist-stimulated receptor
activity (i.e., acted as receptor-sensitizing agents). Two out of eight human anti-beta1-AR
increased basal but decreased agonist-stimulated receptor activity (i.e., acted as partial
agonists).
CONCLUSIONS Antibodies against the same small beta1-AR domain can have very divergent allosteric effects,
ranging from inhibitory to agonist-promoting activities. Activating autoantibodies were
associated with severe cardiac dysfunction and thus might be involved in the development
and/or course of human cardiomyopathy. (J Am Coll Cardiol 2000;36:1280–7) © 2000 by
the American College of Cardiology
A majority of hormones and neurotransmitters exert their
physiological effects through G protein–coupled receptors.
In addition, antibodies specifically directed against certain
members of this superfamily have been shown to be able to
affect receptor-mediated cellular signaling as well (1). Some
of these antibodies are supposed to be involved in the
initiation and/or course of several human autoimmune
diseases: Receptor-modulating autoantibodies have been
found against the thyrotropin receptor, nicotinic acetylcho-
line receptor, and the insulin receptor, suggesting an impli-
cation in the pathogenesis of Graves’ disease (2), myasthenia
gravis (3), and type B insulin-resistant diabetes (4), respec-
tively. More recently, autoantibodies targeting the human
beta1-adrenergic receptor (beta1-AR) have been detected in
a substantial fraction of patients with idiopathic dilated
cardiomyopathy (DCM) (5–7) and, with lower frequency,
also in patients with ischemic cardiomyopathy (ICM) (7).
Because of the use of different strategies for the detection
and characterization of such anti-beta1-AR autoantibodies
the reports on their prevalence, their functional properties,
and their (supposed) pathophysiological role are not yet
conclusive.
In this study we used an approach based on several newly
developed recombinant tools (7–10) to investigate whether
and to what extent anti-beta1-AR might interfere with
receptor-signaling: As a first step, we utilized fusion pro-
teins with selected domains of the human beta1-AR (11) to
generate heterologous anti-beta1-AR in rabbits (polyclonal)
and mice (monoclonal). We then utilized recombinant
human beta1-AR expressed in various cells to characterize
their immunological and functional properties (7,8,12).
Finally, these properties were compared with those of
selected human anti-beta1-AR autoantibodies, representa-
tive for a certain subgroup of cardiomyopathic patients
(7,13).
METHODS
Generation of heterologous antibodies against the hu-
man beta1-adrenergic receptor. Fusion proteins of bacte-
rial glutathion-S-transferase (GST) and the aminoterminus
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(N), carboxyterminus (C), or second extracellular domain
(ECII) of the human beta1 (11) and beta2-AR (14) were
produced in Escherichia coli as previously described (8). To
generate anti-beta1-AR in rabbits and mice, 50 to 100 mg of
the purified beta1-AR fusion proteins in incomplete
Freund’s adjuvant were administered subcutaneously (New
Zealand White rabbits) or intraperitoneally (Balb/c mice).
Subsequent boosts were given at four-week intervals; mice
received an additional antigen boost intravenously three
days prior to fusion. Sera were drawn 6 and 12 weeks after
immunization and assayed for reactivity with the corre-
sponding antigens by enzyme-linked immunoassay
(ELISA). The IgG was prepared from immunoreactive
rabbits by caprylic acid precipitation and immunopurified
using sodium dodecyl sulfate (SDS)-denatured recombinant
human beta1-AR expressed in Sf9 cells (8). For monoclonal
antibodies, the spleens from immunoreactive mice were
removed and fused with nonsecreting Ag8 myeloma cells
(15) as described elsewhere (16). Three weeks after fusion
the supernatants of the hybridomas were assayed for immu-
noreactivity by ELISA; positive clones were subcloned by
the limiting dilution technique (17), and subtype and
concentration of the produced immunoglobulins were de-
termined by a commercially available kit (Boehringer
Mannheim, Germany).
Preparation of human IgG fractions. Thirty patients
suffering from idiopathic dilated cardiomyopathy (DCM)
were included in the present study (6 women and 24 men;
mean age: 55 6 9 years; NYHA functional class III–IV; left
ventricular diastolic volume .110 ml/m2; see Table 1).
According to the recently defined criteria (7), DCM was
diagnosed when coronary heart disease was excluded by
angiography, and when exposure to cardiotoxic substances,
myocarditis, or other systemic heart diseases were not
evident from clinical history. All patients were stable under
therapy with angiotensin-converting enzyme (ACE)-
inhibitors, diuretics, nitrates, and digitalis. None of them
received beta-receptor agonists or beta-blockers. The IgG
was prepared from the sera either 1) by direct caprylic acid
precipitation (n 5 20) or 2) by nonselective immunoadsorb-
tion and elution from protein G columns as previously
described (13), also followed by caprylic acid precipitation
(n 5 10). Prior to the assays all samples were extensively
dialyzed against phosphate buffered saline (PBS) and nor-
malized to 1,000 mg IgG/ml (7). Control IgG was obtained
from 15 healthy subjects with normal left ventricular func-
tion (4 women and 11 men; mean age 49 6 11 years; see
Table 1).
Enzyme-linked immunoassay. Supernatants of B cell hy-
bridomas (mouse spleen-/Ag8-cells), immunopurified rab-
bit antibodies, and human IgG-preparations were assayed
for immunoreactivity first by a conventional ELISA: GST
was cleaved off from the fusion proteins (see above) by
thrombin, and fragments corresponding to selected domains
of the human beta1- or beta2-AR (N-terminus, C-terminus,
and ECII-domain, respectively) were coated onto 96-well
plates (5 ng protein/well). Bovine serum albumin (BSA) and
a nonreceptor peptide served as specificity controls (7). The
antigens were either reduced or not with 1% beta-
mercaptoethanol (beta-Me) and incubated with serially
diluted antibodies for 2 h at 37°C (rabbit anti-beta1-N/-C/-
Abbreviations and Acronyms
anti-beta1-AR/-ECII 5 antibodies against the beta1-
adrenergic receptor/second
extracellular loop of the beta1-
adrenergic receptor
beta1-AR 5 beta1-adrenergic receptor
beta-Me 5 beta-mercaptoethanol
BSA 5 bovine serum albumin
DCM 5 dilated cardiomyopathy
ELISA 5 enzyme-linked immunoassay
GST 5 glutathion-S-transferase
IBMX 5 isobutylmethylxanthine
PBS 5 phosphate buffered saline
SDS 5 sodium dodecyl sulfate
Table 1. Clinical and Hemodynamic Data of Patients and Healthy Subjects†
Parameter
DCM (1)
DCM (2)
(n 5 22)
Healthy Subjects
(n 5 15)
Subgroup A
(n 5 6)
Subgroup B
(n 5 2)
General
Age (yrs) 56 6 5 53 6 9 55 6 8 49 6 11
Gender: female/male 2/4 0/2 4/18 4/11
NHYA functional class 3.2 6 0.3* 3.1 6 0.4* 2.6 6 0.5 0
Heart rate (min21) 89 6 3* 88 6 5* 84 6 6 69 6 18
LV Angiography
SVR (dynzszcm25) 1,404 6 104 1,410 6 18 1,420 6 115 n.d.
LVEF (%) 29.2 6 3.2** 28.5 6 2.1** 37.2 6 5.2 n.d.
CI (1zmin21zm22) 2.26 6 0.4* 2.20 6 0.3* 2.79 6 0.5 n.d.
Cont. (mm Hgzs21) 752 6 87* 729 6 38* 858 6 113 n.d.
†Mean values 6 SD. Patients with dilated cardiomyopathy (DCM), who were positive (1) or negative (2) for functionally active
anti-beta1-ECII were compared by the Student t-test for unpaired samples. Significant differences between DCM (1) and
DCM (2) are denoted by *p , 0.05 or **p , 0.005.
SVR 5 systemic vascular resistance; CI 5 cardiac index; LVEF 5 left ventricular ejection fraction (ventriculography);
Cont. 5 contractility (peak dP/dt), derived from left ventricular high fidelity time/pressure curves; n.d. 5 not determined.
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ECII: 50 to 32,000-fold; mouse IgM: 50- to 1,280-fold;
human IgG: 5 to 500-fold). Bound antibodies were detected
with appropriate species-specific horseradish peroxidase
conjugated secondary antibodies and o-phenylene-diamine
(Sigma, Deisenhofen, Germany) as substrate. Optical den-
sities were read at 490 nm.
Western-blotting and immunoprecipitation. The SDS-
lysates (2% SDS, 1% beta-Me, 60 mmol/liter Tris-HCl, pH
6.4) of Sf9 cells infected either with recombinant Autogra-
pha californica nuclear polyhedrosis virus AcMNPV-
beta1-AR (Sf9-beta-1-cells; Fig. 1, R), or with wildtype
virus (negative control; Fig. 1, C) (8) were transferred to
nitrocellulose membranes and incubated with serially di-
luted antibodies for 12 h at 4°C (rabbit anti-beta-1-N/-C/-
ECII: 500- to 15,000-fold; mouse IgM: 10- to 1,000-fold;
human IgG: 5- to 100-fold). Immunoreactive bands were
visualized by appropriate species-specific horseradish perox-
idase conjugated secondary antibodies and enhanced che-
moluminescence (ECL, Amersham, Buckinghamshire,
UK).
For immunoprecipitation, the membrane proteins of Sf9
cells with (R) or without (C) human beta1-AR were
biotinylated with D-biotinoyl-e-aminocaproic acid (Boehr-
inger), and then precipitated as previously described in
detail (8). Briefly, antibodies (two different dilutions: rabbit
anti-beta1-N/-C/-ECII, 1:100/250; mouse IgM, 1:10/25;
human IgG, 1:5/10) were incubated with the supernatants
of solubilized cells for 12 h at 4°C before the addition of
g-bind protein G-Sepharose (Pharmacia, Freiburg, Germa-
ny), and for monoclonal IgM antibodies a further secondary
goat anti-mouse antibody (Sigma). After incubation of the
precipitation reactions for another 2 h at 4°C, protein
G-Sepharose was washed six times with PBS, and the
adsorbed proteins were eluted with nonreducing 5% SDS-
sample buffer. For detection of biotinylated receptors the
eluates were transferred to nitrocellulose membranes by
Western blotting and probed with horseradish-peroxidase
coupled streptavidin (Boehringer). Bound streptavidin was
detected by enhanced chemoluminescence (Amersham).
Indirect immunofluorescence microscopy. Immunofluo-
rescence studies on Sf9 cells with (R) or without (C) human
beta1-AR were performed as previously described (7,8). The
cells were either transferred to glass slides, fixed with 4%
formaldehyde (10 min, 4°C) and permeabilized with 0.1%
Triton X-100 (30 s, 4°C), or, when native receptors were
analyzed, directly suspended in PBS containing 2 mmol/
liter MgCl2 and 2% BSA. For both conditions a single
antibody-dilution was utilized (rabbit anti-beta1-N/-C/-
ECII 1:200; mouse IgM, 1:50; human IgG, 1:5). After
incubation for 1 h at 20°C (fixed and permeabilized cells) or
6 h at 4°C (native intact cells) appropriate species-specific
CY3-conjugated secondary antibodies (Dianova, Hamburg,
Germany) were added to detect receptor-bound rabbit,
mouse, or human antibodies by a Zeiss-Axioplan fluores-
cence microscope (Carl Zeiss Jena, Oberkochen, Germany).
Radioligand binding. Binding of the radiolabeled antago-
nist [3H]CGP 12177 (NEN-DuPont, Boston, Massachu-
setts) to recombinant human beta1-AR expressed in Sf9
cells (1–2 3 106 beta1-AR per cell) (7,8) was measured by
liquid scintillation counting after incubating 25,000 cells or
membranes from 50,000 cells with 3 3 10212 to 5 3 1029
mol/liter [3H]CGP 12177 (30 min, 30°C). Experiments
were performed in triplicate on both intact cells and
membranes 1) either in the presence or absence of a fixed
antibody concentration (mouse, 7 nmol/liter; rabbit, 70
nmol/liter; human IgG, 2 mmol/liter) and various concen-
trations of [3H]CGP 12177, or 2) at constant 3 nmol/liter
[3H]CGP 12177 with various concentrations of the differ-
ent antibodies (mouse, 7 3 10210 to 7 3 1028 mol/liter;
rabbit, 2 3 1029 to 7 3 1027 mol/liter; human, 2 3 1027
to 7 3 1026 mol/liter). Saturation curves were fitted to the
data by computer-aided nonlinear regression analysis, as-
suming binding to a single class of sites with uniform
affinity. Nonspecific binding was determined in the presence
of 1 mmol/liter unlabeled CGP 12177 and subtracted from
the data.
Assays on receptor-mediated cellular signaling (cAMP-
assay). The cAMP-assay was carried out on stably trans-
fected Chinese hamster fibroblasts expressing 100–120
fmol/mg human beta1-AR (CHW-beta1 cells). In brief,
confluent cells were incubated with the same antibody
concentrations as indicated above (radioligand binding) for
1 h at 37°C in the presence of 0.5 mmol/liter isobutylmeth-
ylxanthine (IBMX) (7,10,12). After stimulation with 10
mmol/liter (2)isoprenaline (15 min, 37°C) cytoplasmic
cAMP was extracted from the cells with boiling water and
Figure 1. Detection of anti-beta1-AR by various approaches. (a) Western
blots of crude cell lysates, and (b) immunoprecipitates of membrane-
biotinylated Sf9 cells expressing recombinant human beta-1-AR (R) or the
wildtype vector (C), and (c) fixed and permeabilized, or (d) intact unfixed
Sf9-beta1 cells were probed with either (a, c, d) domain-specific rabbit
anti-beta1-N/-ECII/-C (Rabbit) or mouse anti-beta1-ECII (Mouse), or
(b) with POD-coupled streptavidin (see Methods). Their respective
immunoreactivities are compared with those of anti-beta1-ECII-positive
or -negative cardiomyopathic patients (Human, Pat. b1-Pos./-Neg.). Note,
that SDS-denatured beta1-AR (lane a) are stained less clearly (Rabbit) or
not at all (Mouse, Human) by anti-beta1-ECII antibodies, whereas all of
them immunoprecipitate (lane b) or recognize the native beta1-AR (lane
d).
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measured by 125I-labeled scintillation proximity assay (Bio-
trak Kit, Amersham). An additional series of cAMP exper-
iments served to analyze the effects of functionally active
rabbit (70 nmol/liter) or human anti-beta1-AR (2 mmol/
liter) on various states of (agonist-induced) receptor-activity
after stimulation of CHW-beta1 cells with increasing
amounts of (2)isoprenaline (10212 to 1025 mol/liter). All
experiments were repeated three times.
Statistics. The threshold for a significantly increased reac-
tivity in ELISA was based on the statistical distribution
(mean 6 2 SD, 95% confidence interval [CI]) of the values
obtained for preimmune sera (rabbits, n 5 6) or IgG-
fractions from healthy control subjects (human, n 5 15).
Two-factor analysis of variance (ANOVA) was used to
analyze the overall cAMP-response (functional assays).
Significance between the antibody subgroups was analyzed
by the Scheffe´ F test (post hoc multiple comparison proce-
dure). A p value ,0.05 was considered to be statistically
significant. Clinical and hemodynamic parameters of
autoantibody-positive and -negative patients were com-
pared by the Student t test for unpaired samples. All data are
given as mean 6 SD.
RESULTS
Immunological characterization of receptor antibodies.
Antibodies against the human beta1-AR (anti-beta1-AR)
were generated in rabbits and mice, or prepared from the
sera of cardiomyopathic patients. Their respective immuno-
reactivities were determined as previously described (7) 1) by
a peptide-based ELISA, 2) by Western blotting, and 3) by
immunoprecipitation and immunofluorescence. The results
are summarized in Table 2 and Figure 1: The rabbit
antibodies directed against the amino (N)- or carboxyter-
minus (C) of the beta1-AR were equipotent in recognizing
their corresponding peptide-antigens in reduced or nonre-
duced form (Table 2), and clearly stained and/or precipi-
tated intact native human beta1-AR expressed in Sf9 cells
(Fig. 1, rabbit, lanes a and b). Antibodies directed against
the second extracellular receptor domain were sensitive to
reduction of the antigen (Table 2) but were also able to
recognize the receptors in Western blots (with a lower signal
intensity compared to antibodies against the N- or
C-terminus) and to immunoprecipitate the receptors (Fig.
1, rabbit). The monoclonal mouse antibody (of an IgM
subtype and lower affinity) directed against the beta1-ECII
domain had a similar pattern of immunoreactivity: The
antigen treatment with beta-Me led to a decrease in
sensitivity for the beta1-ECII peptide (Table 2), and dena-
tured beta1-AR of SDS-treated Sf9-beta1 cells were not
stained at all (Fig. 1, mouse, lane a). By contrast, the
antibodies could immunoprecipitate the beta1-AR from
biotinylated Sf9-cells, giving a streptavidin-positive band on
the blots (Fig. 1, mouse, lane b).
From human IgG preparations, none of the healthy
Table 2. Titers of Human, Rabbit, and Monoclonal Mouse Anti-beta1-AR Obtained for
ELISA, Western Blotting, and Immunoprecipitation
Detection Method
Antibody
Rabbit IgG
(Polyclonal, Immunopurified)
Mouse IgM
(Monoclonal)
Human IgG
(Polyclonal)
Beta1-N Beta1-ECII Beta1-C Beta1-ECII
Pat. beta1-pos.
(n 5 8)†
Control
(n 5 15)†
ELISA
Antigen reduced*
Beta1-N 1:32000 — — — — —
Beta1-ECII — 1:6400 — 1:100 1:10 —
Beta1-C 1:100 — 1:32000 — — —
Beta2-N — — — — — —
Beta2-ECII — — — — — —
Beta2-C — — 1:800 — — —
Antigen nonreduced
Beta1-N 1:32000 1:100 — — — —
Beta1-ECII — 1:32000 — 1:640 1:160 —
Beta1-C 1:100 — 1:32000 1:20 1:20 —
Beta2-N 1:100 — — — — —
Beta2-ECII — 1:200 — 1:40 — —
Beta2-C — — 1:1600 — 1:10 —
Western blot 1:10000 1:1000 1:15000 — — —
Immunoprecipitation 1:250 1:250 1:250 1:25 1:10 —
*Reduction of the antigen was done by treatment with 1% beta-Me. †One representative example for each of the two subgroups
is given. Values given correspond to the maximum dilution at which 1) a statistically significant signal was obtained in ELISA
(p , 0.05 vs. background, see Methods), or 2) a clear receptor band (Mr 45) was detectable in Western blots or
immunoprecipitates (Fig. 1). Negative results at a dilution of 1:100 for rabbit-, 1:10 for mouse-, or 1:5 for human antibodies are
indicated by a dash.
Beta1- and beta2-N/-ECII/-C for the N-terminus, second extracellular domain, or C-terminus of the human beta1 or
beta2-AR; Pat. beta1-pos. for the subgroup of patients with antibodies able to recognize native beta1-AR (n 5 8/30), and
Control for IgG-preparations from healthy subjects (n 5 15).
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control subjects (n 5 15) had a significant titer of anti-
beta1-AR antibodies, whereas 47% of the cardiomyopathic
patients (n 5 14/30) had autoantibodies able to bind to
synthetic peptide-antigens corresponding to selected do-
mains of the human beta1- or beta2-AR (not shown).
However, only a subgroup of these patients (n 5 8/14) had
functionally relevant anti-beta1-AR able to precipitate na-
tive human beta1-AR from cell membranes (Fig. 1, human,
line b). None of them recognized SDS-denatured beta1-AR
on Western blots (Fig. 1, human, lane a), which is in
agreement with our previous results (7). All of these
antibodies showed increased reactivity with the beta1-ECII
peptide-antigen, but only in its nonreduced form (Table 2).
Taken together, these results indicate that anti-beta1-
ECII preferentially or exclusively recognize a conforma-
tional epitope within the ECII-domain of the beta1-AR,
which can be denatured by reducing agents or by SDS
treatment. This notion was further supported by immuno-
fluorescence experiments: The Sf9-beta1 cells were either
fixed and permeabilized (Fig. 1, lane c), or untreated cells
were directly incubated with the different antibodies (Fig. 1,
lane d). None of the rabbit, mouse or human anti-beta1-
ECII recognized beta1-AR on fixed Sf9 cells, whereas all of
them immunostained the receptor, when it was natively
presented on intact Sf9-beta1 cells. In contrast, rabbit
anti-beta1-N stained both fixed and unfixed Sf9-beta1 cells
with the same intensity, and rabbit anti-beta1-C stained
only fixed, permeabilized Sf9-beta1 cells (Fig. 1, rabbit,
lanes c and d). The IgG preparations from healthy subjects
gave negative results throughout in both Western blots and
immunoprecipitation and/or fluorescence experiments (not
shown).
Interference of receptor antibodies with ligand binding.
The results from radioligand-binding studies brought fur-
ther evidence for the recognition of a native receptor
conformation by anti-beta1-ECII. Only these antibodies
were able to decrease binding of [3H] CGP 12177 to
recombinant human beta1-AR in a concentration-
dependent manner (Fig. 2a): The antibodies raised in
rabbits or mice were more potent inhibitors compared to
anti-beta1-ECII from cardiomyopathic patients and de-
creased [3H] CGP 12177 binding by 55 6 3% (mean 6
SD; rabbit IgG, 700 nmol/liter) or 48 6 5% (mouse IgM,
70 nmol/liter) compared to only 24 6 11% by human
receptor autoantibodies (patient IgG, 7 mmol/liter). Similar
results were obtained for intact Sf9-beta1 cells and mem-
brane preparations from these cells (not shown).
The [3H] CGP 12177 saturation curves in the presence
of a fixed concentration of anti-beta1-ECII antibodies
(mouse, 7 nmol/liter; rabbit, 70 nmol/liter; human, 2
mmol/liter) revealed that all of them decreased total ligand
binding capacity (Bmax) by about the same extent (from
8.2 6 0.1 [mean 6 SD; control] to 6.3 6 0.3 [rabbit], 6.2 6
0.2 [mouse], or 5.9 6 0.4 pmol/mg [human], respectively,
p , 0.001; Fig. 2b). Interestingly, human and rabbit
anti-beta1-ECII also decreased [
3H] CGP 12177 affinity
(KD) by about 2- or 4-fold (from 0.38 6 0.04 [mean 6 SD;
control] to 0.74 6 0.1 [human] or 1.34 6 0.02 nmol/liter
[rabbit], respectively) indicating some degree of allosteric
competition between the radioligand and these antibodies.
By contrast, rabbit anti-beta1-N/-C and IgG-preparations
from autoantibody-negative patients and/or healthy control
subjects did not significantly affect [3H] CGP 12177 bind-
ing to the beta1-AR (Fig. 2b).
Effects of receptor antibodies on receptor-mediated sig-
naling. Antibody effects on transmembrane signaling were
analyzed on stably transfected CHW-beta1 cells (7,12).
Only anti-beta1-ECII were able to modulate intracellular
cAMP levels (Fig. 3); however, their effects on receptor-
mediated signaling differed considerably (Table 3): The
rabbit and mouse anti-beta1-ECII significantly decreased
both basal and isoprenaline-stimulated cAMP accumulation
Figure 2. Decrease in ligand-binding to human beta1-AR expressed in Sf9
cells (a) in the presence of constant 3 nmol/liter [3H]CGP 12177 and the
indicated concentrations of anti-beta1-AR, or (b) in the presence of a fixed
concentration of the different anti-beta1-AR (mouse, 7 nmol/liter; rabbit,
70 nmol/liter; human: 2 mmol/liter) and various concentrations of
[3H]CGP 12177 (3 3 10211 to 5 3 1029 mol/liter). Error bars indicate
the mean 6 SD of three experiments. Bmax 5 total ligand binding capacity;
KD 5 receptor-ligand dissociation constant.
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in a concentration-dependent manner, and this inhibition
was particularly evident at higher agonist concentrations
(Fig. 4, rabbit anti-beta1-ECII). Because these antibodies
inhibited not only the agonist-stimulated but also the basal
cAMP production, their functional properties might be best
characterized as inverse agonists. By contrast, the majority
of the anti-beta1-ECII autoantibodies from cardiomyo-
pathic patients (n 5 6/8, patient-subgroup A) increased
basal (p , 0.02) and even further increased agonist-
stimulated cAMP production (on top of the stimulation
obtained with 10 mmol/liter (2)isoprenaline, p , 0.002;
Fig. 3 and Table 3). Again, this effect appeared to be more
pronounced at higher agonist concentrations (Fig. 4,
patient-subgroup A).
Interestingly, two of the autoantibody-positive patients
(n 5 2/8, patient-subgroup B) had anti-beta1-ECII, which
affected beta1-AR activity in a manner that could be placed
between these two opposite fashions of modulating receptor
signaling. These antibodies increased basal but decreased
isoprenaline-stimulated cAMP accumulation dependent on
the degree of receptor activation (Fig. 4): In the presence of
very low amounts of agonist intracellular cAMP production
was still increased (10212 mol/liter (2)isoprenaline; p ,
0.05), whereas it was inhibited at higher agonist-
Figure 3. Increase in basal or (2)isoprenaline (10 mmol/liter)-stimulated
cAMP-levels upon incubation of CHW-beta1 cells with the indicated
concentrations of rabbit, mouse or human anti-beta1-ECII (open sym-
bols), or rabbit anti-beta1-C/-N (filled circles/triangles). IgG-
preparations from healthy subjects served as a control (filled diamonds).
Error bars indicate the mean 6 SD of three experiments.
Figure 4. Increases in (2)isoprenaline-stimulated cAMP-levels (10212 to
1025 mol/liter) upon incubation of CHW-beta1 cells with a fixed concen-
tration of rabbit (70 nmol/liter) or human anti-beta1-ECII (2 mmol/liter;
patient-subgroups A and B). Filled circles or diamonds correspond to the
values obtained for rabbit anti-beta1-C or IgG-preparations from healthy
subjects, respectively. Error bars indicate the mean 6 SD of three
experiments. Significance between control values (filled symbols) and
those obtained in the presence of anti-beta1-ECII (open symbols) was
analyzed by the Scheffe´ F test. All the values obtained for patient
anti-beta1-ECII (subgroups A/B) differed significantly (p , 0.05) from
control values in the presence of low (10212 to 10210 mol/liter) or high
(1029 to 1025 mol/liter) isoprenaline concentrations, except those from
patient subgroup B at 10210 mol/liter isoprenaline (p 5 0.15, not
significant).
Table 3. Basal and (2)Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the
Presence of Rabbit (70 nmol/liter), Mouse (7 nmol/liter), or Human Anti-beta1-ECII (2
mmol/liter)†
Assay Condition
Control
IgG
Anti-beta1-ECII Antibodies
Rabbit Mouse
Human
Subgroup A Subgroup B
Basal 52 6 4 32 6 5* 43 6 6* 63 6 4* 61 6 6*
1 5 mmol/liter bisoprolol 51 6 5 54 6 6 53 6 7
10 mmol/liter (2)isoprenaline 294 6 18 223 6 31** 138 6 26** 418 6 35** 228 6 27*
15 mmol/liter bisoprolol 56 6 5 57 6 9 58 6 7
†Values are mean 6 SD, given in [fmoles cAMP/104 CHW-beta1 cells]. Significance between the antibody subgroups was
analyzed by the Scheffe´ F test. Significant differences (compared to control IgG) are denoted by *p , 0.05; **p , 0.005.
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concentrations (1029 to 1025 mol/liter (2)isoprenaline;
p , 0.05 to p , 0.02). Thus, their functional properties
might be compared with those of a partial agonist. All
functional effects of agonist- and/or partial agonist-like
human anti-beta1-ECII were abolished in the presence of 5
mmol/liter bisoprolol, indicating that the antibodies acted,
indeed, via the beta1-AR (Table 3).
Although not a main issue of this study, an analysis of the
clinical and hemodynamic parameters of our patient-
collectives revealed that left ventricular function was signif-
icantly more reduced in anti-beta1-ECII-positive (n 5 8)
than in antibody-negative (n 5 22) DCM-patients (Table
1). However, because of the restricted number of antibody-
positive patients in the present study we were not able to
determine specific clinical (i.e., age, duration of disease,
medication) or hemodynamic (i.e., heart rate, left ventricu-
lar ejection fraction, cardiac index) features related to the
prevalence of agonist-like (subgroup A) or partial agonist-
like (subgroup B) anti-beta1-ECII autoantibodies.
DISCUSSION
Anti-beta-receptor antibodies and receptor function.
Antibodies against certain G protein-coupled receptors can
affect receptor signaling, and such effects have been postu-
lated to play a pathophysiological role in several human
diseases (1–7,18,19). The present study shows that in the
case of the beta1-AR, only those antibodies that were
directed against the ECII-loop domain (anti-beta1-ECII)
recognized a native receptor conformation in a variety of
assays (ELISA, immunoprecipitation/-fluorescence), and
that the same antibodies also affected receptor function. In
contrast, antibodies directed against the N- or C-terminus
were not sensitive to denaturation of the receptor and had
no effects on receptor function.
The ligand binding pocket of beta-AR is thought to be
formed by the transmembrane helices. In the case of the
beta2-AR, amino acids in helices III, V, and VI have been
assigned an anchoring function for agonists (20,21). These
data suggest that extracellular loops do not directly partic-
ipate in ligand binding; however, reduction or mutations of
cysteine residues in the extracellular loops of the beta2-AR,
most notably the ECII-domain, result in a reduction of
agonist and antagonist affinities (22). Thus, correct folding
of this loop may be essential for correct formation of the
ligand binding pocket and might explain, why anti-beta1-
ECII can affect ligand binding.
In addition, such antibodies can also affect receptor
function, and these functional effects are of a very different
nature for different antibodies, suggesting that they act as
allosteric regulators of receptor activity: Antibodies binding
to the ECII-loop might reduce or stabilize conformational
changes of the receptors, which are similar to those induced
by agonist or partial agonist ligands (1,9,18,20–23). All of
our anti-beta1-ECII interact with the rather small stretch of
amino acids that form this loop but have different effects on
receptor function. One possible explanation for this diver-
gence is that they recognize the receptor preferentially
(rabbit) or exclusively (mouse, human) in a native confor-
mation; it is possible that among the native conformations
some antibodies recognize the active and others the inactive
form (1,18). With exception of the mouse antibody, because
of the anti-beta1-ECII described here are polyclonal, they
may in fact recognize different conformational states within
the targeted receptor domain. Finally, our data suggest that
both the subtype (i.e., IgG or IgM) and the source of an
immunoglobulin (i.e., the species it stems from) may influ-
ence its respective functional properties as well.
Allosteric effects of antibodies against the second extra-
cellular receptor domain. The functional effects of anti-
beta1-ECII may be discussed according to a model (23) that
assumes two states for receptors, inactive (R) and active
(R*). Agonists (A) can bind to both states, but induce
and/or stabilize the active state, forming preferentially AR*.
Antibodies (5 immunoglobulins, I) can bind to the active
(IR*) or inactive (IR) states, and can also do so in the
presence of agonist. Our mouse and rabbit anti-beta1-ECII
reduced the amount of active receptors, probably by stabi-
lizing an inactive state IR. In the presence of agonist, they
have a similar inhibitory effect, either because they reduce
agonist binding (again forming IR), or because they return
the receptors to an inactive state even with agonist bound
(AIR). These two antibodies behave as inverse agonistic
allosteric regulators, because they inhibit basal as well as
stimulated receptor activities. In contrast, all of the func-
tionally active human anti-beta1-ECII increased basal re-
ceptor activity, presumably by forming an active state (IR*).
Again, they may do so by preferentially binding to the active
state R* (as suggested for antibodies against the beta2-AR
[18]), or by inducing an active receptor conformation (IR*).
In the presence of agonist, most human anti-beta1-ECII
autoantibodies caused a further increase in activity (patient-
subgroup A), whereas only a minor fraction decreased
agonist-induced beta1-AR activity (patient-subgroup B).
The allosteric effects caused by the latter antibodies appear
comparable to those of a partial agonist. Antibodies from
patient-subgroup A may either induce a state AIR*, which
is more active than the agonist-activated state AR*, or
alternatively, cause more receptors to switch into the active
state than even high agonist concentrations do.
Conclusions and perspectives. In summary, antibodies
recognizing a same small domain of the beta1-AR can have
very divergent functional effects. A subgroup of patients
suffering from certain cardiac disorders has been shown to
have circulating autoantibodies to the human beta1-AR
(5–7,12), and like those of the patient-subgroup A reported
here, some of these antibodies appear to have agonist-like
properties and/or act as receptor-sensitizing agents. In the
present study, we focused on patients with DCM; however,
it should be remembered that functionally active anti-beta1-
ECIIs have also been found in ischemic cardiomyopathy
(ICM), although with less frequency (7). Because antibody-
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induced adrenergic (over-)stimulation might contribute to
worsening cardiac dysfunction in both cases (7) sensitizing
anti-beta1-ECII may represent a negative prognostic factor
in DCM and/or ICM. In agreement with this hypothesis,
the antibody-positive DCM-patients here analyzed had a
significantly poorer left ventricular function compared to
those without such antibodies (Table 1); however, because
of the restricted number of antibody-positive patients, we
were not able to identify clinical features characteristic for
type A (agonist-like) or type B (partial agonist-like) anti-
beta1-AR autoantibodies. In the following it will be inter-
esting to study, whether these antibody subtypes are related
to clinical (and/or hemodynamic) parameters, and whether
they are of predictive value.
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